Lupin moves up on launching Risperidone for extended-release injectable suspension
Lupin is currently trading at Rs. 2065.00, up by 12.10 points or 0.59% from its previous closing of Rs. 2052.90 on the BSE.
The scrip opened at Rs. 2045.95 and has touched a high and low of Rs. 2065.00 and Rs. 2045.95 respectively. So far 2444 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2068.70 and Rs. 1972.05 respectively. The current market cap of the company is Rs. 93946.85 crore.
The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 47.06% and 6.06% respectively.
Lupin has launched Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials, with 180-day CGT exclusivity in the U.S. This follows the recent approval received from the United States Food and Drug Administration (USFDA). This is Lupin’s first product using proprietary technology from PrecisionSphere, the long-acting injectable (LAI) platform developed by Lupin’s subsidiary Nanomi B.V.’s (Nanomi).
Nanomi’s LAI platform has demonstrated efficacy and safety in drug delivery. Its proprietary PrecisionSphere technology creates uniform microspheres that deliver extended-release profiles from weeks to months, superior injectability through smaller needles, and consistent drug concentrations. Lupin is expanding the reach of its PrecisionSphere technology by fostering collaborations with companies looking to extend their product lifecycles.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
